Efficacy of Pentoxifylline on Primary Nephrotic Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

April 30, 2011

Conditions
Nephrotic Syndrome
Interventions
DRUG

pentoxifylline

Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M

DRUG

Corticosteroid

Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

lead

National Taiwan University Hospital

OTHER

NCT00354731 - Efficacy of Pentoxifylline on Primary Nephrotic Syndrome | Biotech Hunter | Biotech Hunter